A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia

NCT06986174 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Waldenström Macroglobulinemia
Lymphoplasmacytic Lymphoma
B-Cell Lymphoproliferative Disorder
Indolent Lymphoma

Interventions

DRUG: Pacritinib

Sponsor

Shayna Sarosiek, MD

Collaborators

[object Object]